VCAM1 and atherosclerosis: In addition, preclinical data have suggested that canagliflozin might reduce infarct size (Lim et al., 2019), delay the progression of atherosclerosis, and downregulate the expression of adhesion molecules and inflammatory molecules, including vascular cell adhesion molecule-1 and monocyte chemotaxis protein-1 (Nasiri-Ansari et al., 2018).